Your browser doesn't support javascript.
loading
Carrying SNP rs17506395 (T > G) in TP63 gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso.
Traoré, Lassina; Savadogo, Mousso; Zouré, Abdou Azaque; Kiendrebeogo, Touwendpoulimdé Isabelle; Soudre, Fabienne Marie B T B; Dabre, Soayebo; Traore, Aida Djé Djénéba; Adico, Marc Donald Wilfried; Lare, Tilate; Ouedraogo, Teega-Wendé Clarisse; Ouedraogo, Rogomenoma Alice; Ouattara, Abdoul Karim; Yelemkoure, Edwige T; Sawadogo, Alexis Yobi; Zongo, Nayi; Bambara, Hierrhum Aboubacar; Nadembega, Christelle W; Djigma, Florencia W; Simpore, Jacques.
Afiliação
  • Traoré L; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Savadogo M; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Zouré AA; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Kiendrebeogo TI; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Soudre FMBTB; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Dabre S; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Traore ADD; Biomedical Research Laboratory (LaReBio), Biomedical and Public Health Department, Health Sciences Research Institute (IRSS/CNRST), 03 BP 7192 Ouaga 03, Burkina Faso.
  • Adico MDW; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Lare T; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Ouedraogo TC; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Ouedraogo RA; Laboratory Department, University Hospital Centre-Yalgado OUEDRAOGO, Joseph KI-ZERBO University, UFR/SDS, 03 BP 7021, Ouagadougou 03, Ouagadougou, Burkina Faso.
  • Ouattara AK; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Yelemkoure ET; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Sawadogo AY; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Zongo N; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Bambara HA; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Nadembega CW; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
  • Djigma FW; Laboratory of Molecular and Genetic Biology (LABIOGENE), Joseph KI-ZERBO University, 03 BP 7021, Ouagadougou 03, Burkina Faso.
  • Simpore J; Pietro Annigoni Biomolecular Research Centre (CERBA), 01 BP 364, Ouagadougou 01, Burkina Faso.
Open Life Sci ; 19(1): 20220847, 2024.
Article em En | MEDLINE | ID: mdl-38585642
ABSTRACT
Genetic alterations in the TP63 (GenBank NC_000003.12, ID 8626) and CCR5 (receptor 5 chemokine co-receptor) (GenBank NC_000003.12, ID 1234) genes may increase the risk of developing breast cancer. The aim of this study was to investigate the probable involvement of polymorphisms rs17506395 in the TP63 (tumour protein 63) gene and the CCR5Δ32 mutation in the occurrence of breast cancer in Burkina Faso. This case-control study included 72 patients and 72 controls. Genotyping of SNP rs17506395 (TP63) was performed by polymerase chain reaction-restriction fragment length polymorphism, and genotyping of the CCR5Δ32 mutation was performed by allele-specific oligonucleotide polymerase chain reaction. For SNP rs17506395 (TP63), the genotypic frequencies of wild-type homozygotes (TT) and heterozygotes (TG) were, respectively, 27.72 and 72.22% in cases and 36.11 and 63.89% in controls. No mutated homozygotes (GG) were observed. For the CCR5Δ32 mutation, the genotypic frequencies of wild-type homozygotes (WT/WT) and heterozygotes (WT/Δ32) were 87.5 and 13.5%, respectively, in the cases and 89.29 and 10.71%, respectively, in the controls. No mutated homozygotes (Δ32/Δ32) were observed. None of the polymorphisms rs17506395 of the TP63 gene (OR = 1.47, 95% CI = 0.69-3.17, P = 0.284) and the CCR5Δ32 mutation (OR = 1.32, 95% CI = 0.46-3.77; P = 0.79) were associated with the occurrence of breast cancer in this study.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article